<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67031">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01757639</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02990</org_study_id>
    <secondary_id>NCI-2012-02990</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>CDR0000744584</secondary_id>
    <secondary_id>J1276</secondary_id>
    <secondary_id>9214</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <nct_id>NCT01757639</nct_id>
  </id_info>
  <brief_title>Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of ipilimumab in treating patients
      with relapsed or refractory high-risk myelodysplastic syndrome or acute myeloid leukemia.
      Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some
      block the ability of cancer cells to grow and spread. Others find cancer cells and help kill
      them or carry cancer-killing substances to them.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the safety and toxicity associated with the administration of ipilimumab in
      terms of dose limiting toxicities (DLT), and maximally-tolerated dose (MTD) in a cohort of
      patients with high risk myelodysplastic syndrome who failed hypomethylating therapy, and
      patients with acute myeloid leukemia (AML) who underwent induction therapy but are not
      planned for further intensive chemotherapy. (Dose-escalation) II. Determine the optimal dose
      of ipilimumab for the dose-expansion phase of the trial. (Dose-escalation) III. Better
      define immunologic profiles associated with ipilimumab use in terms of regulatory T-cells
      (T-regs) dynamic changes in 2 separate cohorts of myelodysplastic syndrome (MDS) and AML
      patients at the optimal dose level. (Dose-expansion) IV. Obtain preliminary efficacy data of
      ipilimumab in terms of complete response (CR), partial response (PR), and hematological
      improvement (HI) in both cohorts. (Dose-expansion)

      SECONDARY OBJECTIVES:

      I. Define immunologic profiles associated with ipilimumab use in terms of T-regs dynamic
      changes at different dose levels. (Dose-escalation) II. Define toxicity profiles of
      ipilimumab at the optimal dose in both patient cohorts. (Dose-expansion) III. Obtain
      preliminary data on potential correlations between noted ipilimumab-induced immunologic
      changes and observed toxicity and clinical responses. (Dose-expansion)

      OUTLINE: This is a dose-escalation study.

      INDUCTION: Patients receive ipilimumab intravenously (IV) on day 1. Treatment repeats every
      21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

      MAINTENANCE: Patients receive ipilimumab IV on day 1. Treatment repeats every 12 weeks for
      up to 4 courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at least monthly for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of DLT of ipilimumab by grading and tabulation using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>42 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in percentages of T-regs</measure>
    <time_frame>Baseline to up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in T-regs percentages at designated time points will be correlated with clinical responses and toxicity after ipilimumab. The response will be modeled as the vector for each individual from multiple measures of T-regs percentages as a function of time and group (MDS vs AML). T-regs percentages will be transformed onto the log-scale, and t tests will be used to compare groups at specific time points. Regression models that use generalized estimating equations will be implemented when all time points are considered to account for within-subject correlation of repeated measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as defined by the International working group 2006 (IWG-2006) criteria for CR, PR, HI</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Regression models that use generalized estimating equations (GEE) will be implemented when all time points are considered to account for within-subject correlation of repeated measures. The agreement between immunologic and clinical response will be evaluated with McNemar's test, separately by cohort. 95% confidence limits will be provided as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From start of study to progression or death, assessed up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be reported with a 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From start of study to death, assessed up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be reported with a 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (ipilimumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION: Patients receive ipilimumab IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients receive ipilimumab IV on day 1. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ipilimumab)</arm_group_label>
    <other_name>anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody</other_name>
    <other_name>MDX-010</other_name>
    <other_name>MDX-CTLA-4</other_name>
    <other_name>monoclonal antibody CTLA-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ipilimumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be able to understand and voluntarily sign an informed consent form

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Life expectancy of greater than 6 months

          -  Must have one of the following diagnoses:

               -  Pathologically confirmed chronic myelomonocytic (CMML) or myelodysplastic
                  syndromes (MDS) with high risk features at the time of referral for trial as
                  defined by:

                    -  Intermediate (INT)-2 or high International Prognostic Scoring System (IPSS)
                       score

                    -  Secondary MDS (defined as MDS developing in a patient with an antecedent
                       hematologic disorder or any patient with prior chemotherapy or radiation
                       exposure)

                    -  INT-1 MDS with excess blasts (&gt;= 5% blasts in bone marrow [BM]) or red
                       blood cell (RBC) transfusion-dependency

                    -  MDS progressing to oligoblastic acute myelogenous leukemia (AML) with
                       21-30% BM blasts

                    -  CMML with &gt;= 5% marrow blasts, or RBC or platelet transfusion-dependency,
                       abnormal karyotype, or proliferative features (white blood cell count
                       &gt;=13,000/ÂµL, splenomegaly on physical examination, or extramedullary
                       disease)

                    -  All patients are required to have failed to respond or relapsed after an
                       initial response to hypomethylating agents 5-azacitidine or decitabine or
                       have refused to receive hypomethylating therapy; failure to respond is
                       defined as failing to achieve a CR, PR or HI after at least 4 cycles of
                       hypomethylating therapy; these patients could have received other therapies
                       or not, but must have received hypomethylating therapy or have refused to
                       receive hypomethylating therapy

               -  Pathologically confirmed AML patients who have received one or two courses of
                  induction chemotherapy or hypomethylating agent therapy AND no plans for further
                  chemotherapy therapy, but remain with residual disease of &lt; 5% blasts in BM, by
                  morphology, cytogenetics, fluorescent in situ hybridization (FISH), polymerase
                  chain reaction (PCR) or flow cytometry

          -  Patients must not have received any other treatment for their disease, including
             hematopoietic growth factors, within three weeks of beginning the trial, and should
             have recovered from all toxicities of prior therapy (to grade 0 or 1)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of =&lt; 2 at study entry
             ECOG, or Karnofsky &gt;= 60%

          -  Calculated creatinine clearance by Modification of Diet in Renal Disease (MDRD)
             (CrCL) &gt; 50 ml/min/1.73 squared meter

          -  Total bilirubin =&lt; 2.0 mg/dL unless due to Gilbert's syndrome, hemolysis, or
             ineffective hematopoiesis

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x
             upper limit of normal (ULN)

          -  Females of childbearing potential must have a negative serum or urine pregnancy test
             within 72 hours prior to start of ipilimumab

          -  Patients must have no clinical evidence of central nervous system (CNS) or pulmonary
             leukostasis, disseminated intravascular coagulation, or CNS leukemia

          -  Patients must have no serious or uncontrolled medical conditions

        Exclusion Criteria:

          -  Any serious medical condition, uncontrolled intercurrent illness including, but not
             limited to, ongoing or active infection, symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia, laboratory abnormality, or psychiatric
             illness/social situations that would limit compliance with study requirements or
             prevent the subject from signing the informed consent form

          -  Pregnant or breast feeding females (lactating females must agree not to breast feed
             while taking ipilimumab)

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study

          -  Use of any other experimental drug or therapy within 21 days of baseline

          -  Known hypersensitivity to ipilimumab or history of allergic reactions attributed to
             compounds of similar chemical or biologic composition to ipilimumab

          -  Prior use of ipilimumab, other cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
             blocking therapies, anti-programmed cell death 1 (PD 1) antibody, cluster of
             differentiation (CD) 137 agonist or other immune activating therapy such as anti-CD
             40 antibody within the last 3 months of enrollment in the study; if any of these of
             these agents were used more than 3 months earlier to enrollment in study, the patient
             should have recovered from all toxicity and at least 3 months had passed since last
             use to allow for clearance and observation of any other side effects from the
             previous therapy

          -  Concurrent use of other anti-cancer agents or treatments, including other
             investigational agents

          -  Autoimmune disease: patients with a history of inflammatory bowel disease, including
             ulcerative colitis and Crohn's disease, are excluded from this study, as are patients
             with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic
             progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune
             vasculitis [e.g., Wegener's granulomatosis]); central nervous system (CNS) or motor
             neuropathy considered of autoimmune origin (e.g. Guillain-Barre syndrome and
             Myasthenia Gravis, multiple sclerosis)

          -  Patients with known immune impairment who may be unable to respond to anti-CTLA-4
             antibody

          -  Patients with known other cancers, including brain metastases

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier

          -  Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C
             infections should be excluded because of potential effects on immune function and/ or
             possible drug interactions

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with ipilimumab
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B. Smith</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University/Sidney Kimmel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale-New Haven Hospital North Haven Medical Center</name>
      <address>
        <city>North Haven</city>
        <state>Connecticut</state>
        <zip>06473</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven D. Gore</last_name>
      <phone>203-737-7103</phone>
      <email>steven.gore@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Steven D. Gore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. D. Smith</last_name>
      <phone>410-614-5068</phone>
      <email>bdsmith@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>B. D. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark G. Frattini</last_name>
      <phone>212-851-4872</phone>
      <email>mgf2122@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Mark G. Frattini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew C. Foster</last_name>
      <phone>919-843-2447</phone>
      <email>matthew_foster@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew C. Foster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology at Baylor Irving Cancer Center</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Y. Levy</last_name>
      <phone>800-422-9567</phone>
      <email>mylevy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Moshe Y. Levy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>December 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cytotoxic T-lymphocyte antigen 4</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
